Lord, Abbett & Co’s Immunocore IMCR Stock Holding History

Lord, Abbett & Co’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-100,784	Closed	-$3.04M	–	593
2026 Q1	$3.04M	Buy	+100,784	New	+$3.26M	0.01%	505

Other funds holding IMCR

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Lord, Abbett & Co's IMCR Position: Q2 2026 in Review

Lord, Abbett & Co sold out of Immunocore (IMCR) in Q2 2026, closing a stake of 100,784 shares — an estimated $3.04M sold.

Lord, Abbett & Co first reported a position in IMCR in Q1 2026 and held it in 1 quarter. The position peaked at $3.04M in Q1 2026. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

Lord, Abbett & Co reported no remaining Immunocore position as of Q2 2026 after selling out during the quarter.
Lord, Abbett & Co sold 100,784 Immunocore shares in Q2 2026, an estimated $3.04M.
Lord, Abbett & Co first reported a position in Immunocore in Q1 2026 and held it in 1 quarter.
Lord, Abbett & Co's Immunocore position peaked at $3.04M in Q1 2026.
136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.